Marker Therapeutics Inc (MRKR) FinancialsMRKRFinancialMarker Therapeutics Inc

Evaluating the bottom line, Marker Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -284.46%, while the net margin is -267.94%. These profitability ratios, combined with a Return on Equity (ROE) of -76.87%, provide a clear picture of how effectively MRKR converts its operational activities into shareholder value.

In the context of the broader market, MRKR competes directly with industry leaders such as JSPR and ENLV. With a market capitalization of $24.34M, it holds a leading position in the sector. When comparing efficiency, MRKR's gross margin of N/A stands against JSPR's N/A and ENLV's N/A. Such benchmarking helps identify whether Marker Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Marker Therapeutics reported a FY GAAP EPS of -$0.79, beating expectations, and generated $3.55M in revenue, although this reflects a 46.1% year-over-year decline.